PRF Technologies (PRFX) Convertible Debt (2019 - 2025)

PRF Technologies' (PRFX) quarterly Convertible Debt came in at $50000.0 in Q2 2025, down 89.54% on a QoQ basis from $478000.0 in Q4 2023.

PRF Technologies (PRFX) Convertible Debt (2019 - 2025) Analysis & Trends

PRF Technologies (PRFX) has 4 years of Convertible Debt data on file, last reported at $50000.0 in Q2 2025.

Quarterly Convertible Debt changed N/A year-over-year to $50000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $50000.0 (changed N/A YoY) and the FY2023 annual result came in at $478000.0, changed N/A from the prior year.
Convertible Debt fell to $50000.0 in Q2 2025, from $478000.0 in the prior quarter.
In the past five years, Convertible Debt ranged from a high of $478000.0 in Q4 2023 to a low of $50000.0 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-
10	PRF Technologies	654,452.72	-3.49 Mn	-

Download Data